Ridgetech Inc.
RDGT · Retail-Drug Stores and Proprietary Stores · EDGAR filings ↗
Reference price $1.60 — last insider sale, 2026-06-16 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
C61Small China pharma wholesaler with flattering returns but a freshly restructured business and serious governance/concentration risks.
Strengths
- Top-decile reported ROA (94th pct) and ROE (87th pct), with net margin at 68th pct
- Positive FCF (~$1.1M) and adequate liquidity (current ratio 1.74)
Risks
- Returns are distorted by the Feb-2025 retail divestiture/discontinued ops and a thin 3.2% gross margin (6th pct); revenue is shrinking (-3.2%) and net income fell sharply (4.8th pct)
- Heavy China-VIE governance, key-customer concentration (Jiuzhou) and HFCAA/dividend-repatriation risk
Key metrics
Gross margin
3.2%
Operating margin
-0.9%
Net margin
8.5%
Return on equity
34.4%
Return on assets
15.8%
Revenue growth (QoQ)
-3.2%
Current ratio
1.7×
Free cash flow
$1M
EBITDA
$102K
Tangible book value
$25M
Cash & investments
$13M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | HRT FINANCIAL LP | Sell | 58K | $1.60 |
| 2026-06-15 | HRT FINANCIAL LP | Sell | 8.1K | $1.60 |
| 2026-06-12 | HRT FINANCIAL LP | Sell | 6.5K | $1.51 |
| 2026-06-11 | HRT FINANCIAL LP | Buy | 19K | $1.61 |
| 2026-06-10 | HRT FINANCIAL LP | Buy | 14K | $1.62 |
| 2026-06-09 | HRT FINANCIAL LP | Buy | 25K | $1.78 |
All non-derivative Form 4 activity (SEC), newest first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-07-28 | 2025-03-31 | 0001213900-25-067924 ↗ |
| 20-F | 2024-07-30 | 2024-03-31 | 0001013762-24-002657 ↗ |
| 20-F | 2023-06-15 | 2023-03-31 | 0001213900-23-049280 ↗ |
| 20-F | 2022-07-28 | 2022-03-31 | 0001213900-22-042481 ↗ |